Burning Rock Biotech Limited American Depositary Shares (BNR) — Analysis Summary
Burning Rock Biotech Limited American Depositary Shares (BNR) has a market cap of $105.46M with year-over-year revenue growth of +4.9%. Net margin stands at -10.3%. The stock trades at a P/E ratio of -13.7.
Key Takeaways
- Revenue changed +4.9% year-over-year
- Net margin of -10.3%
- P/E ratio of -13.7
Compared with its sector, BNR posted revenue growth of +4.9% and trades at a P/E of -13.7.
Burning Rock Biotech Limited American Depositary Shares (BNR)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -1828.3x — earnings do not cover interest payments
Operating margin at -10.2% — material operating losses
The latest filing shows negative free cash flow.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
Employees
667
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.